[2]
Johann, P.D.; Erkek, S.; Zapatka, M.; Kerl, K.; Buchhalter, I.; Hovestadt, V.; Jones, D.T.W.; Sturm, D.; Hermann, C.; Segura Wang, M.; Korshunov, A.; Rhyzova, M.; Gröbner, S.; Brabetz, S.; Chavez, L.; Bens, S.; Gröschel, S.; Kratochwil, F.; Wittmann, A.; Sieber, L.; Geörg, C.; Wolf, S.; Beck, K.; Oyen, F.; Capper, D.; van Sluis, P.; Volckmann, R.; Koster, J.; Versteeg, R.; von Deimling, A.; Milde, T.; Witt, O.; Kulozik, A.E.; Ebinger, M.; Shalaby, T.; Grotzer, M.; Sumerauer, D.; Zamecnik, J.; Mora, J.; Jabado, N.; Taylor, M.D.; Huang, A.; Aronica, E.; Bertoni, A.; Radlwimmer, B.; Pietsch, T.; Schüller, U.; Schneppenheim, R.; Northcott, P.A.; Korbel, J.O.; Siebert, R.; Frühwald, M.C.; Lichter, P.; Eils, R.; Gajjar, A.; Hasselblatt, M.; Pfister, S.M.; Kool, M. Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes.
Cancer Cell, 2016,
29(3), 379-393.
[
http://dx.doi.org/10.1016/j.ccell.2016.02.001] [PMID:
26923874]
[9]
Jarrold, J.; Davies, C.C. PRMTs and Arginine Methylation : Cancer’s Best-Kept Secret? Trends Mol. Med., 2019, 1-16. just accep
[40]
Liu, L-M.; Sun, W-Z.; Fan, X-Z.; Xu, Y-L.; Cheng, M-B.; Zhang, Y. Methylation of C/EBPα by PRMT1 Inhibits Its Tumor-Suppressive Function in Breast Cancer. Cancer Res., 2019, 79, 2865-2877.
[52]
Nakai, K.; Xia, W.; Liao, H.W.; Saito, M. Mien-chie Hung, M.C.; Yamaguchi, H. The Role of PRMT1 in EGFR Methylation and Signaling in MDA-MB-468 Triple-Negative Breast Cancer Cells. Breast Cancer, 2017, 7, 2587-2599.
[56]
Zhu, Y.; He, X.; Lin, Y-C.; Dong, H.; Zhang, L.; Chen, X.; Wang, Z.; Shen, Y.; Li, M.; Wang, H.; Sun, J.; Nguyen, L.X.; Zhang, H.; Jiang, W.; Yang, Y.; Chen, J.; Müschen, M.; Chen, C.W.; Konopleva, M.Y.; Sun, W.; Jin, J.; Carlesso, N.; Marcucci, G.; Luo, Y.; Li, L. Targeting PRMT1-Mediated FLT3 Methylation Disrupts Maintenance of MLL- Rearranged Acute Lymphoblastic Leukemia. Blood, 2019, 134(15), 1257-1268.
[108]
Elakoum, R.; Gauchotte, G.; Oussalah, A.; Wissler, M.; Clément-duchêne, C.; Vignaud, J.; Guéant, J.; Namour, F. Biochimie CARM1 and PRMT1 are Dysregulated in Lung Cancer without Hierarchical Features., 2014, 97, 210-218.
[116]
Fedoriw, A.; Rajapurkar, S.R.; O’Brien, S.; Gerhart, S.V.; Mitchell, L.H.; Adams, N.D.; Rioux, N.; Lingaraj, T.; Ribich, S.A.; Pappalardi, M.B.; Shah, N.; Laraio, J.; Liu, Y.; Butticello, M.; Carpenter, C.L.; Creasy, C.; Korenchuk, S.; McCabe, M.T.; McHugh, C.F.; Nagarajan, R.; Wagner, C.; Zappacosta, F.; Annan, R.; Concha, N.O.; Thomas, R.A.; Hart, T.K.; Smith, J.J.; Copeland, R.A.; Moyer, M.P.; Campbell, J.; Stickland, K.; Mills, J.; Jacques-O’Hagan, S.; Allain, C.; Johnston, D.; Raimondi, A.; Porter Scott, M.; Waters, N.; Swinger, K.; Boriack-Sjodin, A.; Riera, T.; Shapiro, G.; Chesworth, R.; Prinjha, R.K.; Kruger, R.G.; Barbash, O.; Mohammad, H.P. Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.
Cancer Cell, 2019,
36(1), 100-114.e25.
[
http://dx.doi.org/10.1016/j.ccell.2019.05.014] [PMID:
31257072]
[117]
Yoshimatsu, M.; Toyokawa, G.; Hayami, S.; Unoki, M.; Tsunoda, T.; Field, H.I. Dysregulation of PRMT1 and PRMT6, Type I Arginine Methyltransferases, is Involved in Various Types of Human Cancers 2011, 1, 562-573.